Author:
Laubach J P,Mahindra A,Mitsiades C S,Schlossman R L,Munshi N C,Ghobrial I M,Carreau N,Hideshima T,Anderson K C,Richardson P G
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference125 articles.
1. Alexanian R, Barlogie B, Dixon D . High dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 1986; 105: 8–11.
2. Gertz MA, Garton JP, Greipp PR, Witzig TE, Kyle RA . A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma. Leukemia 1995; 9: 2115–2118.
3. Barlogie B, Smith L, Alexanian R . Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310: 1353–1356.
4. Anderson H, Scarffe JH, Ranson M, Young R, Wieringa GS, Morgenstern GR et al. VAD chemotherapy as remission induction for multiple myeloma. Br J Cancer 1995; 71: 326–330.
5. Gertz MA, Kalish LA, Kyle RA, Hahn RG, Tormey DC, Oken MM . Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group study. Am J Clin Oncol 1995; 18: 475–480.
Cited by
76 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献